SCHEMBL17455974

SCHEMBL17455974

c1ccc(CN2CCC(Oc3cccnc3-c3ccncn3)CC2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.50
▸ SCN9A Q15858 6/20 0.48
▸ GMNN O75496 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ DRD2 P14416 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ DRD4 P21917 1/20 0.46
▸ DRD3 P35462 1/20 0.46
▸ PMP22 Q01453 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ SCN5A Q14524 4/20 0.45
▸ KCNH2 Q12809 2/20 0.45
▸ ROCK1 Q13464 1/20 0.44
▸ SCN1A P35498 3/20 0.43
▸ SCN8A Q9UQD0 3/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17455963 0.87 SMN1; SMN2 (0.52) SMN1; SMN2SCN9ASCN5AKCNH2ROCK1
SCHEMBL17455968 0.85 SMN1; SMN2 (0.53) SMN1; SMN2SCN9AGMNNALDH1A1LMNA
SCHEMBL17455914 0.80 MCHR1 (0.52) SMN1; SMN2SCN9ACYP2D6SCN5AKCNH2
SCHEMBL17456046 0.79 MCHR1 (0.53) SMN1; SMN2SCN9AGMNNALDH1A1LMNA
SCHEMBL17455980 0.79 SMN1; SMN2 (0.58) SMN1; SMN2SCN9AGMNNALDH1A1LMNA
SCHEMBL4111325 0.78 SMN1; SMN2 (0.60) SMN1; SMN2SCN9AGMNNALDH1A1LMNA
SCHEMBL17456050 0.77 SCN9A (0.49) SMN1; SMN2SCN9ALMNADRD2DRD4
SCHEMBL17455988 0.77 KDM4E (0.46) SMN1; SMN2SCN9ASCN1ASCN8AGAA
SCHEMBL17456021 0.77 SCN9A (0.43) SMN1; SMN2SCN9ADRD2DRD4DRD3
SCHEMBL17455978 0.76 MCHR1 (0.47) SMN1; SMN2CYP2D6ROCK1SCN1ASCN8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 SMN1; SMN2 23/4885SCN9A 565/4885GMNN 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback